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Determining Associations between 
Human Diseases and non-coding 
RNAs with Critical Roles in 
Network Control
Haruna Kagami1, Tatsuya Akutsu2, Shingo Maegawa3, Hiroshi Hosokawa3 & Jose C. Nacher1
Deciphering the association between life molecules and human diseases is currently an important 
task in systems biology. Research over the past decade has unveiled that the human genome 
is almost entirely transcribed, producing a vast number of non-protein-coding RNAs (ncRNAs) 
with potential regulatory functions. More recent findings suggest that many diseases may not 
be exclusively linked to mutations in protein-coding genes. The combination of these arguments 
poses the question of whether ncRNAs that play a critical role in network control are also enriched 
with disease-associated ncRNAs. To address this question, we mapped the available annotated 
information of more than 350 human disorders to the largest collection of human ncRNA-protein 
interactions, which define a bipartite network of almost 93,000 interactions. Using a novel 
algorithmic-based controllability framework applied to the constructed bipartite network, we found 
that ncRNAs engaged in critical network control are also statistically linked to human disorders 
(P-value of P = 9.8 × 10−109). Taken together, these findings suggest that the addition of those genes 
that encode optimized subsets of ncRNAs engaged in critical control within the pool of candidate 
genes could aid disease gene prioritization studies.
RNA research has attracted increasing attention in recent years. Empirical evidence shows that most 
of the encoded information in the genomes of higher organisms, such as mammals, is transcribed into 
non-protein-coding RNAs (ncRNAs), which can be explained by the unbalanced complexity scale between 
prokaryotic and eukaryotic organisms1. Although these RNA molecules are not further translated into 
proteins, they can still play key biological functions in a cell. Numerous families of ncRNAs have been 
identified and classified, including rRNAs, tRNAs, snRNAs (small nuclear RNAs), snoRNAs (small nucle-
olar RNAs), miRNAs (micro RNAs) and many long ncRNAs. These molecules can be expressed in cells, 
but rather than coding a specific protein, they target and modify the expression of other biomolecules2. 
Whereas infrastructural RNAs (rRNAs and tRNAs) have been typically assigned to functions related 
to protein synthesis, small RNA molecules (snoRNAs, miRNAs and siRNAs) have shown the ability to 
perform multilevel regulatory tasks by altering protein expression levels3. For example, miRNAs can be 
involved in cell growth, stem cell functions, cell proliferation and embryonic development4 and have 
been found to target the genes with high transcriptional regulation complexity5. Moreover, numerous 
researchers have reported multiple associations between non-coding RNAs and complex diseases, includ-
ing viral infections and oncogenesis6–11. There is evidence indicating that mutations and dysregulation 
of miRNAs may result in various diseases12–15. These findings have recently led to the development of 
promising miRNA-targeting therapeutics16,17.
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Although the sequence information of ncRNAs is available, until recently, the interactions between 
specific ncRNAs and other protein molecules have not been collected and classified in large numbers. A 
recent major update of the NPInter database v2.018, which includes more than 200,000 interactions (only 
700 were reported in v1.019) of ncRNAs with other bio-molecules from 18 organisms, including humans, 
with almost 93,000 interactions, offers a promising opportunity to investigate the large-scale structure 
of the ncRNA-protein interaction network and to determine to what extent each ncRNA is engaged in 
network regulation and control using the latest advances in network controllability.
Recent developments in network science have provided a variety of methods to investigate the 
controllability feature in large-scale networks in directed20 and undirected unipartite networks21,22. 
Developments in structural controllability in bipartite networks using the Minimum Dominating Set 
(MDS) have also provided the necessary methodology to formalize its study23. Molnár et al. exhaustively 
investigated the variations of the MDS with respect to various types of network structures using a greedy 
algorithm24. On the biological side, the application of domination techniques is also promising. A hit-
ting set formulation, which is equivalent to set cover in bipartite networks, has been used to uncover 
14 anticancer drug combinations using data from 60 tumor derived cell lines25. Domination analysis of 
biological networks has shown a statistically significant enrichment of topological central genes in aging, 
cancer, infectious diseases, and signaling pathways26. Wuchty investigated the controllability in protein 
interaction (PPI) networks (a unipartite network) and discovered that an optimized subset of proteins 
(MDS) was enriched with essential, cancer-related, and virus-targeted genes27. Moreover, these identified 
proteins are highly involved in regulatory functions, showing high enrichment in transcription factors 
and protein kinases, and participate in regulatory links, phosphorylation events, and genetic interactions. 
However, previous biological analyses were performed using only one of the multiple MDS configura-
tions. Because the computation of the MDS does not lead to a unique set of controllers, it is possible to 
perform a more precise network control analysis and to distinguish between several control categories, 
such as critical, intermittent and redundant20,28. Hence, the controllers can be classified into three classes 
depending on how they are engaged in network control. Moreover, PPI is a unipartite network, and in 
this work, we focus on a bipartite network (ncRNA-protein interactions), which increases the analysis 
complexity.
Here, we present a novel computational procedure to calculate the fraction of critical, intermittent 
and redundant nodes in a bipartite network, which extends previous computational methodology spe-
cifically derived for unipartite networks20. By using the proposed algorithmic framework implemented 
on bipartite networks and human ncRNA disease associations collected from the HMDD29 and OMiR30 
databases, we can identify an optimized subset of ncRNA controllers that exhibits a statistically signifi-
cant enrichment with human disorder classes, unveiling a novel link between ncRNA molecules that are 
highly involved in critical network control and specific diseases.
Methods
ncRNA-protein interactions and diseases associations datasets. Interactions between non-cod-
ing RNA and proteins were retrieved from the NPInter database v2.018. This database consists of exper-
imentally reported interactions between non-coding RNAs and other biomolecules, including proteins, 
RNAs and genomic DNAs. We selected the human organism and extracted the molecular interactions 
corresponding to ncRNAs and proteins, which led to a subset of 3,894 ncRNAs, 5,783 proteins and 
92,998 interactions. We used the HMDD database (version 2)29 and the OMiR database30 for human 
microRNA and disease associations and for associations between ncRNAs and “orphan” Mendelian dis-
eases, respectively (see SI for details).
Determining the minimum set of critical controllers in the ncRNA-protein network. We ana-
lyzed the controllability features of the non-coding RNA-protein bipartite network. A bipartite graph 
G(VT,VB; E) consists of a set of top nodes VT  and a set of bottom nodes VB. A set of edges connects both 
sets of nodes (E ⊆ VT × VB). The set of edges represents directions from VT to VB. A set S ⊆ VT of nodes 
in the graph G is a dominating set if for all nodes w ∈   VB, there exists a node v ∈   VT such that (v, w) 
∈  E. This dominant set (DS) of nodes plays the role of the set of driver nodes23. In our problem, the set 
of top nodes corresponds to ncRNA molecules and the set of bottom nodes to proteins. Hence, the set 
of controllers corresponds to a subset of VT (ncRNAs). The minimum number of ncRNA controllers can 
be identified by calculating the dominating set of minimum cardinality i.e. Minimum Dominating Set 
(MDS)23. The optimal solution for the MDS problem in bipartite network is obtained by using Integer 
Linear Programming (ILP) (see Eq. 1 in the SI). Although it is an NP-hard problem, surprisingly, the 
exact solution can be obtained for large networks up to more than 105 nodes within a few seconds23 (see 
the SI for details). Because the computation of the MDS does not lead to a unique set of controllers, 
we can classify the nodes depending on their network control roles. The novel algorithm that uses an 
MDS-based method to determine the minimum set of critical and redundant controllers for a bipartite 
network is presented in the SI. The set of critical nodes represents those nodes that belong to every MDS 
configuration and therefore always play a role in network control. The set of redundant nodes denotes 
those nodes that never appear in any MDS configuration and therefore are never engaged in controlla-
bility roles. Finally, those nodes that appear in some MDS but not in all MDS configurations are called 
intermittent nodes. The fraction of intermittent nodes ni can be computed from the fractions of critical 
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nc and redundant nr nodes as follows: ni = 1 − nc − nr. We also performed a mathematical analysis to 
theoretically estimate the fraction of critical nodes which is shown in the SI. Enrichment calculation is 
done as in27 (see SI for details).
Results
Network structure of the ncRNA-protein interaction network. Using the NPInter v2.0 database, 
we extracted the molecular interactions corresponding to ncRNAs and proteins in humans. A visual 
representation of the entire network is shown in Fig.  1. The NPInter database includes a number of 
non-coding RNAs classes. A total of 32 classes were involved in the construction of the ncRNA-protein 
interaction network for humans. The color legend in Fig. 1 denotes each main ncRNA class, and Table 1 
shows the statistics of each class. The miRNA class is the third largest class, including 796 molecules, 
after the lncRNAs related classes, and it exhibits the highest average degree. One possible reason for 
these unbalanced degree values is that miRNAs have been studied in more detail than newly discovered 
ncRNA classes, and their interactions and disease associations have been studied more systematically. 
Indeed, Fig. 1 also illustrates that the largest fraction of the interactions corresponds to miRNAs, namely 
the miRNA target interaction and regulatory class, which includes 85,355 (yellow) edges. A second large 
group is composed of 8,162 interaction (green) edges and is associated with the ncRNA-protein binding 
class. Other small groups of interaction classes, such as expression correlation, with only 27 interactions, 
are denoted in grey in Fig. 1.
To analyze the global structure of the bipartite ncRNA-protein interaction network, we used the 
degree distribution. The results shown in Fig. 2(d,e) indicate that the protein degree distribution has a 
range of several decades, compatible with a power-law distribution from kmin = 41.1 ± 5.2 and character-
ized by a degree exponent γ = 3.28 ± 0.15. The degree distribution for the ncRNAs shown in Fig. 2(a–c) 
suggests a more complicated picture. As shown in Table 1, the component related to miRNAs is highly 
connected, and its degree distribution analysis reveals that it tends to decay exponentially. In contrast, 
the rest of the ncRNAs are less densely connected to proteins (see Table 1), and their degree distribution 
tends to follow a power-law decay for low degrees. The asymmetric degree distributions of these two 
large components of the same network are highlighted in Fig.  2(a,b). The explained tendency is more 
evident when the cumulative degree distribution P( > k) is plotted on a log-linear scale, showing that, 
only from high degrees above k > 10, the distribution follows an exponential decay of the form e−λ.k with 
λ = 0.008 ± 0.001.
Three main findings can be derived from this analysis. First, there is a nonzero probability to find 
highly connected proteins interacting with many ncRNAs (see Fig.  2(d,e)). Second, a large fraction of 
ncRNAs interact with a similar number of proteins. Third, the unveiled structure of the ncRNA-protein 
interaction network displays an uncommon topology, characterized by two connected but drastically 
different sub-networks, one led by miRNA and the other consisting of the rest of the ncRNAs, mainly 
Figure 1. Visualization of the bipartite ncRNA-protein interaction network. Color legend denotes each 
main ncRNA class. The largest fraction of the interactions corresponds to the miRNA target interaction 
and regulatory class, which includes 85,355 (yellow) edges. A second large group is composed of 8,162 
interactions (green) edges and is associated with the ncRNA-protein binding class. Proteins (nodes in blue) 
with the highest number of interactions are highlighted. The star symbol indicates that the protein plays a 
‘bridge’ role.
www.nature.com/scientificreports/
4Scientific RepoRts | 5:14577 | DOi: 10.1038/srep14577
dominated by long ncRNAs (lncRNAs). By only removing 11 proteins (highlighted by a star symbol in 
Fig.  1), both large sub-networks become topologically disconnected. The biological functionalities of 
these ncRNA-bridges related proteins are shown in Table 2. Because the tendency of the protein degree 
distribution is a power-law, there should be a small set of highly connected proteins. The degree of each 
hub is also shown in Table  2. Most of the highly connected proteins are related to lncRNA, and low 
degree proteins tend to be associated with the miRNA component.
A small number of ncRNAs control the entire network. The computation of an MDS in the 
bipartite ncRNA-protein interaction network allows us to identify the minimum number of controllers 
needed to achieve full network control (see Fig. 3). The total number of ncRNAs collected in our study 
is 3,894. Among them, only 371 are needed to simultaneously control 5,783 proteins using the MDS 
approach, which represents only 9.5% of the ncRNAs (see Table 1 for the distribution of the MDS size 
in the ncRNA classes). More importantly, we also applied the algorithm to compute the number of 
critical and redundant ncRNAs under the MDS framework. The results show that 335 and 3,419 nodes 
play critical and redundant roles, respectively (see Table 1 for the distribution of the size of the critical 
set in ncRNA classes). Most of the nodes involved in critical control belong to the miRNA class. A small 
fraction of ncRNAs, 140, is engaged in intermittent network control, representing 3.5% of the total ncR-
NAs. By combining the critical and intermittent nodes, the total number of ncRNAs engaged in network 
ncRNA Class # ncRNAs # MDS # Critical Av. Degree <k>
BC200 RNA 1 1 1 8
H19 RNA 1 1 1 9
MESTIT1 RNA 1 1 1 1
RNase P RNA 1 1 1 7
SRP RNA 1 1 1 8
telomerase RNA 1 1 1 8
TSU RNA 1 1 1 2
vault RNA 1 1 1 2
XIST RNA 1 1 1 6
KvLQT1-AS RNA 1 1 0 1
snRNA 9 6 6 7
IPW RNA 2 1 1 1.5
7SK RNA 2 1 1 8.5
Unclassified 19 8 8 1.8
miRNA 796 316 283 107.2
Y RNA 4 1 1 3.7
snoRNA 7 1 1 3.5
scaRNA 8 1 1 3.1
mRNAlike lncRNA 1088 19 18 2.6
lncRNA 1507 6 5 2.2
lincRNA 426 1 1 2.6
bic RNA 1 0 0 1
DISC2 RNA 1 0 0 1
GNAS1-as RNA 1 0 0 1
guide_RNA 2 0 0 4
H_ACA_box_snoRNA 1 0 0 7
NCRMS RNA 1 0 0 1
RNase MRP RNA 2 0 0 7.5
scAlu RNA 1 0 0 3.1
SRP_7SL RNA 3 0 0 1.3
UBE3A antisense RNA 2 0 0 2
aHIF RNA 1 0 0 1
Table 1.  Statistics of the ncRNA and optimized subsets of control. The number of ncRNAs, MDS size, 
critical set size and the average degree for each ncRNA class is displayed.
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control only represents 12.2%. In this bipartite network, the numbers of MDS and critical nodes are 
relatively similar. Unipartite networks, in contrast, tend to show different numbers for MDS and the 
critical set20. However, from a functional viewpoint, the critical nodes are more important because they 
are always engaged in network control regardless of the arbitrarily selected MDS configuration. This 
essential distinction between MDS and critical roles is missing in ref. 27. Figure 3 and Table 1 show that 
a large number of nodes involved in critical control belong to the miRNA class. 
We also performed a simple theoretical analysis to estimate the fraction of critical nodes (See SI for 
details). Table  3 shows the value of Eq. 2 shown in SI and the actual fraction of critical nodes in the 
ncRNA-protein interaction network for each out-degree k. Eq. 2 gives good estimates for low out-degree 
nodes, whereas it does not for larger out-degree nodes, due to degree correlations or heterogeneity.
Enrichment of critical and redundant nodes in ncRNA-protein interactions. To evaluate the 
enrichment of controllability features as a function of the connectivity of the ncRNAs, we classified 
ncRNAs according to their degree in bins of logarithmic increasing size. In each bin class, we computed 
the enrichment as defined in the Methods section. Figure  4 shows that the MDS and Critical set are 
clearly enriched with ncRNAs that have more than 10 outgoing links. Conversely, the redundant set is 
depleted with ncRNAs that have more than 10 interactions. For each ncRNA class, we also investigated 
the enrichment levels (Fig. S1). Although most of the classes are populated by few ncRNAs, some classes 
contain many molecules. Among the latter, miRNAs show the highest enrichment. The largest classes, 
which are related to long non-coding RNAs (lncRNAs), show a depletion in controllability roles. It is 
worth mentioning that the lncRNAs31,32 and the large intergenetic non-coding RNAs (lincRNAs)33,34 are 
novel heterogeneous classes that are rapidly emerging in literature and being progressively associated 
to a myriad of biological functions. However, because they have been discovered much more recently 
than miRNAs, they not only remain less-well understood but also their regulatory interactions are less 
exhaustively catalogued, which may explain their low average degree shown in Fig. 1 and Table 1.
Enrichment of critical and redundant nodes in ncRNA disease associations. Annotations 
regarding disease associations from the HMDD database resources were mapped to the ncRNAs obtained 
from the NPInter database. We then classified the ncRNAs into two groups based on whether they have a 
disease or non-disease association. Another classification was performed for ncRNAs based on whether 



























































Figure 2. Degree and cumulative distributions for ncRNAs and proteins. (a) Decomposition of the out-
degree distribution for miRNAs (purple) and the combination of the rest of the ncRNA classes (orange).  
(b) Degree distribution for all combined ncRNA classes (c) Cumulative degree distribution for the ncRNAs 
on a log-linear scale. (d) In-degree distribution for proteins. (e) Cumulative degree distribution for proteins 
on a log-log scale. Data for the fitting analysis is shown and discussed in the main text.
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they belong to the MDS and the critical set of nodes. Among all possible MDS configurations, we selected 
one and classified the ncRNAs as shown in Table S1 as a contingency table. The total number of different 
diseases included in the database is 367. Using the results shown in Table S1, we applied Fisher’s exact 
test to determine whether the MDS of ncRNAs is significantly enriched with disease associations. The 
result of the test was a two-tailed exact P-value with a strong signal (P = 1.0 × 10−124). Therefore, the 
associations between disease and ncRNAs that belong to the MDS are statistically significant.
Because the MDS is not unique, we focus on those critical nodes that are always engaged in network 
control. The results for the critical set of ncRNAs are shown in Table S1. Applying Fisher’s exact test, 
we found that diseases were significantly enriched in the critical set of ncRNAs with a two-tailed exact 
P-value of P = 9.8 × 10−109. A histogram with the number of ncRNAs that play a critical role in network 
control and associated to each disease is shown in Fig. S2. Out of all diseases, the histogram only shows 
data for the top 28 diseases with the highest number of ncRNAs engaged in critical network control and 
associated with the disease. The histogram is dominated by hepatocellular carcinoma and stomach, breast 
and colorectal neoplasms.
Next, we investigated the enrichment of MDS and the critical set of ncRNAs for each particular 
disease. The results for the top 30 diseases with highest number of ncRNA associations are shown in 
Fig.  5. Next to the enrichment scores, the two-tailed P-values for the Fisher’s exact test are displayed. 
A full list with all diseases is shown in Table S2. The result demonstrates that for each disease, there is 
a significant enrichment in both MDS and the critical set. When only diseases that passed the Fisher’s 
exact test are considered, the enrichment of the critical set is, in most cases, higher than that of the MDS 
(Fig. S3), which reinforces the importance in network control. Moreover, the enrichment function does 
not depend strongly on the size of the MDS or the critical set involved in the disease and, on average, 
is distributed at approximately 0.5 (Fig. S4). The results of the analysis using a different data repository, 
such as the lncRNADisease database, are shown in the SI.
Gene ID Degree Feature Uniprot ID Protein functional description
ELAVL1 1307 Bridge Q15717 Binds avidly to the AU-rich element in FOS and IL3/interleukin-3 mRNAs.
IGF2BP3 713 Bridge O00425 RNA-binding protein that act as a regulator of mRNA translation and stability.
SRSF1 629 Q07955 Plays a role in preventing exon skipping, ensuring the accuracy of splicing and regulating alternative splicing.
IGF2BP2 552 Bridge Q9Y6M1 Binds to the 5′-UTR of the insulin-like growth factor 2 (IGF2) mRNAs.
TARDBP 540 Bridge Q13148 DNA and RNA-binding protein which regulates transcription and splicing.
TIAL1 527 Bridge Q01085 RNA-binding protein. Possesses nucleolytic activity against cytotoxic lymphocyte target cells.
IGF2BP1 522 Bridge Q9NZI8 RNA-binding factor that affects mRNA nuclear export, localization, stability and translation.
FUS 413 P35637 Binds both single-stranded and double-stranded DNA.
PTBP1 327 Bridge P26599 Plays a role in pre-mRNA splicing and in the regulation of alternative splicing events.
TIA1 296 P31483 Involved in alternative pre-RNA splicing and regulation of mRNA translation by binding to AU-rich elements (AREs).
EWSR1 246 Bridge Q01844 Might normally function as a transcriptional repressor.
FUS_mutant 216 P35637 Binds both single-stranded and double-stranded DNA.
AGO1-4 199 Q9UL18; Required for RNA-mediated gene silencing (RNAi).
AGO2 180 Q9UKV8 Required for RNA-mediated gene silencing (RNAi) by the RNA-induced silencing complex (RISC).
TAF15 173 Bridge Q92804 RNA and ssDNA-binding protein that may play specific roles during transcription initiation at distinct promoters.
MOV10 169 Bridge Q9HCE1 Probable RNA helicase. Required for RNA-mediated gene silencing by the RNA-induced silencing complex (RISC).
PUM2 132 Bridge Q8TB72 Sequence-specific RNA-binding protein that regulates translation and mRNA stability.
TNRC6A-C 92 Q8NDV7; Plays a role in RNA-mediated gene silencing by both micro-RNAs (miRNAs) and short interfering RNAs (siRNAs).
QKI 85 Bridge Q96PU8 RNA-binding protein that plays a central role in myelinization.
Table 2.  Annotated information and functionality of proteins with the highest degree. The set of 
proteins with ‘bridge’ features indicate that its removal leads to a disconnected work, as explained in the text.
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Finally, we investigated the ncRNA-disease associations reported in the OMiR dataset. The total num-
ber of diseases included in the database is 79. By applying the Fisher’s exact test to the data shown in 
Table S4, we found that the MDS of the ncRNAs is enriched with orphan diseases (P = 6.0 × 10−43). We 
hypothesized that the critical set of the ncRNAs is also enriched with disease associations. The Fisher’s 
exact test result showed a statistically significant association between the critical set of the ncRNAs and 
the set of “orphan” Mendelian diseases (P = 3.3 × 10−40) (see SI for details).
A novel emerging class of ncRNAs consists of long non-coding RNAs (lncRNAs), which are being 
widely identified in large numbers within mammals and associated to important tasks in many different 
cellular processes such as regulating gene expression at different stages, from epigenetic to transcrip-
tional and post-transcriptional31,32. Recently, Liao et al. predicted the functions of lncRNAs based on 
coding-non-coding gene co-expression network method35. Our approach does not make use of the gene 
expression information. In contrast, the MDS methodology uses the reported experimental biological 
interactions to identify a mathematically optimized set of controllers operating as a critical role. Out 
of 1507 lncRNAs analysed in our work, only six lncRNAs belong to the identified MDS and five out of 
the six were classified as critical controllers. The lncRNA that belongs to the MDS but not to the critical 
set is the RPI001_2629 that interacts with protein O43251 (also known as RNA binding protein fox-1 
Figure 3. Controllability in the ncRNA-protein interaction network. (Left) Visualization of the 
distribution of critical, intermittent and redundant nodes in the entire network. Color indicates node control 
functionality and molecule type as shown in the legend. (Right) Highlight of a network subgraph that 
illustrates an example of critical network control. Network control is indicated by the directed waved lines. 
Ten proteins are controlled by only three ncRNAs playing a critical role. The remaining two ncRNAs are 
redundant.












Table 3.  Comparison of the theoretical predictions and experimental data results. The theoretical 
analysis derives a simple mathematical expression (Eq. 2 in SI) that can estimate the fraction of critical 
nodes in bipartite networks.
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Figure 4. Degree enrichment of the MDS, critical and redundant sets. Enrichment results that show the 
statistical proportion of ncRNAs engaged in a given set S, such as the MDS, critical or redundant, according 
to their degrees.
Figure 5. Disease enrichment of the MDS and critical set. The figure shows the results for the top 30 
diseases with the highest number of ncRNA associations. Next to the enrichment scores for the MDS and 
critical set, the two-tailed P-values for the Fisher’s exact test are displayed. A full list with all diseases is 
shown in Table S2. The result demonstrates that for each disease, there is a significant enrichment in both 
the MDS and critical set. For the statistical significance tests, a two tailed p-value of more (less) than 0.05 
rejects (accepts) the hypothesis of disease association with the MDS and critical set.
www.nature.com/scientificreports/
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homolog 2), and is encoded in the gene RBFOX2. This interaction is classified as ncRNA-protein binding 
interaction class according to the NPInter annotation. In contrast, all of five critical lncRNAs identified 
in our study have been reported as controllers in literature and classified as regulatory interaction classes 
in annotations from NPInter database. They were not, however, identified as regulators by using the 
co-expression network model whose predictions are provided in NONCODE database35. The CBR3-AS1, 
synonym of the PlncRNA-1, is a recently discovered prostate cancer-up-regulated long noncoding RNA, 
which modulates apoptosis and proliferation through reciprocal regulation of androgen receptor36. The 
LINC00312, also known as ERR (estrogen receptor repressor)-10 has been reported as a repressor in 
transcriptional signaling activation of estrogen receptor-alpha37. Next, the long noncoding RNA RNCR2 
(retinal non-coding RNA 2), synonym of MIAT (myocardial infarction associated transcript), plays a 
critical role in regulating mammalian retinal cell fate specification38. The NCRUPAR-PAR1 (ncR-uPAR 
upregulated PAR-1) is a noncoding RNA that regulates human protease-activated receptor-1 gene dur-
ing embryogenesis39. Finally, PVT-1 has been extensively investigated and reported as a regulator of the 
c-Myc gene transcription over a long distance40,41. Note also that all of these five lncRNAs identified as 
critical controllers by our approach are also associated to regulatory classes in NPInter v2.0 database. 
We believe that once lncRNAs and lincRNAs protein interactions are systematically collected and widely 
classified, a more detailed study of their controllability features could be very interesting, which may lead 
to identification of a larger number of controllers associated to critical roles.
The transcripts hsa-miR-20a, -20b, -93, -17, -106a, and -16b are known as the miR-17 family. The 
miR-17 family is related to pivotal biological processes, such as cell cycle regulation, cell death, and 
embryonic development42. All precursors give rise to microRNA with the sequence “AAAGUG” as the 
“seed” sequence. The miR-17 family miRNAs were first identified as an oncogene43,44. In fact, the miR-17 
family microRNAs are overexpressed in human B-cell lymphoma and chronic lymphocytic leukemia42,43. 
In addition, members of the miR-17 family suppress the amyloid precursor protein APP directly in 
vitro45,46. In Alzheimer’s disease, downregulation of miR-106b has been reported in the patients’ brains. 
The multiple roles of the miR-17 family may be the reason why the miR-17 family was detected as 
important hubs in ncRNAs.
ELAVL1, IGF2BP2, IGF2BP3, and PUM2 were identified as hub proteins. These proteins are regu-
lators of the translocation and/or translation of target mRNAs. ELAVL1 physically interacts with the 
AU-rich element in the 3′UTR of target RNAs and stabilizes the bound mRNAs, resulting in activation 
of protein synthesis47,48. In fact, ELAVL1 stabilizes a variety of target mRNAs, especially mRNAs related 
to cancer and inflammation49. IGF2BP2 and 3 also bind target mRNAs and regulate mRNA localization 
and translation of the target mRNAs50. In contrast, PUM2 has been identified as a repressor of trans-
lation from the target mRNAs51. PUM2 may have important roles in germ cell development because 
PUM2 physically interacts with DAZ (Deleted in azoospermia) protein, which is essential for germ cell 
development52. Thus, our method revealed relationships among important microRNAs and RNA-binding 
proteins involved in several biological processes and human diseases.
Some miRNAs in the miR-17 family are critical (or in the MDS) and others are not, which sug-
gests that their functions are slightly different or that currently available data are insufficient. Although 
whether a node is critical (or in the MDS) is a good measure to evaluate the importance of the node, it 
is a binary measure and may not be robust for certain types of small changes of network topology. Future 
work should extend these measures to quantitative ones.
Conclusions
The combination of disease annotation information with bipartite ncRNA-protein interaction network 
allowed us to investigate the statistical association between ncRNA controllers and human disorders and 
eventually led to our main finding. This question was analyzed using polygenic diseases, which included 
cardiovascular and cancer disorder clusters among others and ‘orphan’ Mendelian diseases, of which the 
disorders are typically less studied and are thought to be single-gene diseases53. The association between 
the identified optimized critical set of control nodes and both groups of diseases was statistically signifi-
cant. This means that those ncRNAs that are always engaged in critical network control are also likely to 
be responsible for human disorders, which is our main result. These results also significantly extended 
those by Wuchty27 who only considered the minimum dominating sets in protein interaction network 
(a unipartite network). MDS is useful methodology for analyzing biological networks having bipartite 
structures, but as described above critical nodes are more important than MDS nodes. This work pro-
posed the algorithmic procedure to identify critical nodes in complex bipartite networks.
Disease-associated genes are usually identified using linkage mapping or genome-wide association 
studies. More recently, however, disease module and diffusion-based methods computed on interactome 
networks have also contributed toward identifying disease genes54–56. In any methodology, however, the 
procedure requires a set of candidate genes, excluding ncRNAs, which represent the highest proportion 
of the human genome, to be pre-selected for the analysis. Our findings suggest that the genes that encode 
the small, optimized subset of non-coding RNAs enriched in human disorders and that play a critical 
role in network control could also be added to the pool of candidate genes to aid and improve disease 
gene prioritization.
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